|  |  |  |  |  |
| --- | --- | --- | --- | --- |
|  | Antiplatelets | Vitamin K inhibitors | Antiplatelets + Vitamin K inhibitors | NOACs |
| N | 901 | 1450 | 576 | 439 |
| Age Mean (SD) | 79.6 (10.3) | 75.3 (10.3) | 74.6 (9.4) | 75.5 (9.6) |
| Female Gender n (%) | 460 (51.1) | 739 (50.1) | 223 (38.7) | 226 (51.5) |
| CHA2DS2VASc score. Median (Interquartile range) | 4(3-5) | 4(3-5) | 4(3-5) | 4(3-5) |
| English Index of Deprivation Score. Median (Interquartile Range) | 43.4 (37.6-49.8) | 42.1(36.2-48.8) | 42.7(36.6-49.4) | 41.8(35.3-48.3) |
| Days of exposure Mean (SD) | 897 (633) | 1288 (616) | 764 (623) | 438 (407) |
| TIA or ISn (%) | 117 (13.0) | 132 (9.1) | 30 (5.2) | 14 (3.2) |
| CHDn (%) | 189 (21.0) | 256 (17.7) | 162 (28.1) | 27 (6.2) |
| PAD n (%) | 32 (3.6) | 39 (2.7) | 20 (3.5) | 6 (1.4) |
| GI haemorrhagen (%) | 36 (4.0) | 43 (3.0) | 17 (3.0) | 7 (1.6) |

Table 1. Number of patients, time of exposure, and outcomes in each therapy category.